

Innovative Facility for Isotope GENeration with Efficient Ion Accelerator

Aristotelis Lazopoulos, BIOKOSMOS SA Radiochemist MSc, QP, Site Manager

Kick-off meeting3-4 March 2025
Thessaloniki, Greece







• **BIOKOSMOS S.A.** is a leading radiopharmaceutical company founded in 1992, specializing in Nuclear Medicine and Oncology. With nearly three decades of experience, the company has established itself as a key player in the production and distribution of radiopharmaceuticals, supporting advanced diagnostic and therapeutic applications.



Introduction

BIOKOSMOS S.A. operates two state-of-the-art cyclotron manufacturing sites:

- Headquarters in Lavrio, Athens, operational since 2004, and
- A second facility in Lakkoma, Halkidiki, operational since 2020.

These facilities enable the company to meet growing market demands while ensuring compliance with stringent quality and safety standards.





Our Workforce & Certifications

- BIOKOSMOS S.A. employs a team of 50 highly skilled professionals, including scientists, sales specialists, regulatory and medical affairs experts, administrative personnel, and logistics staff.
- Our commitment to excellence is demonstrated through our **GMP and GDP certifications**, as well as compliance with **ISO 9001:2015 and ISO 13485:2016**, ensuring the highest industry standards in pharmaceutical production and distribution.



Main activities & competencies

- **BIOKOSMOS S.A.** focuses on the production and distribution of radiopharmaceuticals for PET/CT scans.
- Positron Emission Tomography (PET) is a well-established, non-invasive imaging technique that has gained significant clinical importance over the past two decades. PET imaging assesses metabolic activity and blood perfusion in human organs, providing critical insights into various medical conditions, particularly in oncology.



Main activities & competencies

- The company's facilities include:
- > A **Cyclotron** for isotope production.
- > A **Radiopharmaceutical synthesis laboratory**, equipped with six shielded high-purity units housing four PET radiopharmaceutical synthesis modules and two fractionation units.
- > A **Quality control laboratory**, fully equipped to ensure compliance with European Pharmacopoeia standards and national regulatory requirements.
- BIOKOSMOS S.A. strictly adheres to Good Manufacturing Practices (GMP) and employs advanced safety protocols throughout the production process. The synthesis, fractionation, and packaging of radiopharmaceuticals occur in a controlled environment that ensures product integrity and patient safety.



Main involvement in IFIGENEIA

- As part of its continuous growth strategy, **BIOKOSMOS S.A.** actively participates in European research and development programs, fostering innovation in the field of radiopharmaceuticals.
- Our mission is to enhance patient care by delivering high-quality, cutting-edge solutions that support both diagnostics and therapy in nuclear medicine.
- We are committed to expanding our partnerships and collaborating with international stakeholders to drive advancements in the field and improve healthcare outcomes across Europe and beyond



Main involvement in IFIGENEIA

- With a strong foundation in radiopharmaceutical production, an expert team, and a dedication to excellence, **BIOKOSMOS S.A.** is well-positioned to contribute to the future of Nuclear Medicine and Oncology.
- We look forward to engaging in meaningful collaborations that will further the impact of radiopharmaceuticals in patient care.



IFIGENEIA staff

• The company's IFIGENEIA staff include:

Lakkoma site team

- Dr. Eleftherios Halevas, Chemical Engineer, QP & QA manager Task Manager
- Mr. Athanasios Zacharakis, Medical Physicist, Radiation Protection Officer Task Manager
- Mr. Aristotelis Lazopoulos, Radiochemist, Site manager, QP & Production manager

Lavrio site team

- Dr. Charalampos Tsoukalas, Radiopharmacists, QP & Production manager
- Dr. Michael Kaplanis, Radiochemist QP & QA manager
- Mr. Charalampos Kanteler, Medical Physicist



Thank You!



